Clinical Trial Update: Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of surufatinib, sintilimab, and capecitabine for metastatic adenocarcinoma of the small intestine or appendice…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Small Intestine
• Appendiceal Carcinoma

Drugs mentioned

• Capecitabine (capecitabine)
• Sintilimab (sintilimab)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Adenocarcinoma of Small Intestine, Appendix Carcinoma | Phase 2 | Status: RECRUITING